Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the body’s regulatory functions, CKD is accompanied by a wide range of comorbidities and complications. Renal anemia is a common complication of CKD. Treatment options for renal anemia are sought after by physicians, patients, and healthcare systems that face an expanding CKD population. However, safety issues and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of these agents. This content provides a deep dive and longitudinal information on renal anemia market dynamics. It examines the management of dialysis and mid- to late-stage CKD patients from the perspective of nephrologists. How is renal anemia being treated in the United States today, and what are the factors behind treatment decisions? Also included in this content are sales and messaging efforts of key market players and coverage of late-stage products for the treatment of renal anemia.